AACR20 Poster 5615: Assess Human Specific Anti-CD47 Antibodies with hCD47/hSIPRα Double Knock-In Mice

Anti-Human CD47 Antibodies Inhibit hCD47-MC38 Tumor Growth in hCD47/hSIPRα Double Knock-In Mice

Daniel X. He, Chenpan Nie, Lei Zheng, Ruilin Sun*, Annie X. An, Jian Fei*, Henry Q.X. Li, Davy X. Ouyang
*Shanghai Model Organisms Center, Inc., 3577 Jinke Rd, Shanghai, 201203 China

Blockade of CD47/SIRPα signaling with anti-CD47 antibodies offers a promising anticancer therapeutic approach, by unleashing the phagocytic activity of macrophages against tumor cells.

Preclinical animal models are needed to assess anti-CD47 antibodies as potential anticancer therapeutics. Models need to be immunocompetent and express humanized CD47/SIRPα, to allow full recapitulation of the mode of action of anti-CD47 agents.

We’ve developed a human CD47/SIRPα double knock-in mouse model in combination with engineered murine syngeneic MC38 cells expressing human CD47. This poster details model characterization, as well as efficacy data for anti-hCD47 antibodies alone and in combination with anti-mPD-1 agents.

Watch this Poster to Discover:

• How a hCD47/hSIRPα double humanized model, along with a hCD47-MC38 syngeneic cell line, provide a powerful preclinical platform for evaluating the mode of action and in vivo efficacy of human-specific CD47 antibodies
  
  
• That the surface expression of human/mouse chimeric CD47 and SIRPα are consistent with mouse proteins in wild type C57BL/6 mice
  
  
• That anti-hCD47 antibodies inhibit hCD47-MC38 tumor growth in hCD47/hSIPRα double knock-in mice, and the combinatorial effects of anti-mPD-1 agents

Watch the Poster Now!